Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
Researchers analyzed autopsies among people with HIV who died in New York City since 1984.
This is from a large study of U.S. veterans followed for extensive periods.
Researchers followed nearly 10,000 people with hepatitis C, some of whom were treated with direct-acting antivirals.
HIV-positive individuals tend to develop frailty at a younger age than the general population.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Researchers have for the first time properly assessed HIV’s association with this health outcome.
Hepatitis C increases risk of death among people on HIV treatment.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
Researchers eschewed the typical either/or analysis of depression as a risk factor and measured it along a continuum.
A review of randomized controlled trials found that the main apparent benefit of such testing occurred among those with virologic failure.
That’s according to an analysis of HIV-positive people released from jail or prison in Connecticut.
One researcher argues that the pharmaceutical industry ought to pay greater heed to such risks during drug development.
Treating hep C lowers the risk.
The study was conducted in Indonesia, Ukraine and Vietnam.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.